EAM Investors’s Vanda Pharmaceuticals VNDA Stock Holding History

EAM Investors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-110,806	Closed	-$2.9M	–	324
2018 Q4	$2.9M	Buy	+110,806	New	+$2.61M	0.79%	19
2017 Q1	–	Sell	-48,354	Closed	-$771K	–	374
2016 Q4	$771K	Sell	48,354 -22,504	-32%	-$362K	0.1%	285
2016 Q3	$1.18M	Buy	+70,858	New	+$954K	0.16%	233
2014 Q3	–	Sell	-65,936	Closed	-$1.07M	–	359
2014 Q2	$1.07M	Buy	+65,936	New	+$878K	0.2%	283
2013 Q4	–	Sell	-321,548	Closed	-$3.53M	–	358
2013 Q3	$3.53M	Buy	321,548 +56,536	+21%	+$604K	0.7%	12
2013 Q2	$2.14M	Buy	+265,012	New	+$1.78M	0.46%	50

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EAM Investors's VNDA Position: Q1 2019 in Review

EAM Investors sold out of Vanda Pharmaceuticals (VNDA) in Q1 2019, closing a stake of 110,806 shares — an estimated $2.9M sold.

EAM Investors first reported a position in VNDA in Q2 2013 and held it in 6 quarters. The position peaked at $3.53M in Q3 2013. 179 funds tracked by Wall St. Rank hold VNDA as of Q1 2019.

EAM Investors reported no remaining Vanda Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
EAM Investors sold 110,806 Vanda Pharmaceuticals shares in Q1 2019, an estimated $2.9M.
EAM Investors first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 6 quarters.
EAM Investors's Vanda Pharmaceuticals position peaked at $3.53M in Q3 2013.
179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2019.

Based on EAM Investors's 13F filing for Q1 2019, filed 13 May 2019.